Search bioRxiv⌕ Search

Biology subjects

Kubista, H.

Publications and source records attributed to Kubista, H..

2 recordsLinked to original sources

IP3-mediated Ca2+ transfer from ER to mitochondria stimulates ATP synthesis in primary hippocampal neurons

During electrical activity, Ca2+ enhances mitochondrial ATP production, helping to replenish the energy consumed during this process. Most Ca2+ enters the cell via ligand- or voltage-gated channels on the neuronal membrane, where it stimulates the release of additional Ca2+ from the endoplasmic reticulum (ER). Although the influence of cytosolic Ca2+ on neuronal metabolism has been widely investigated, relatively few studies have explored the contribution of ER Ca2+ release in this context. Therefore, we investigated how activity-driven Ca2+ crosstalk between the ER and mitochondria influences the regulation of mitochondrial ATP production. We show that in primary hippocampal neurons derived from rat pups of either sex, depletion of ER Ca2+ led to a reduction in mitochondrial Ca2+ levels during both resting and stimulated states, while exerting only a minimal impact on cytosolic Ca2+ levels. Additionally, impaired ER-mitochondria Ca{superscript 2} transfer led to a reduction in mitochondrial ATP production. Similar effects were observed when inositol-3-phosphate receptors (IP3Rs), but not ryanodine receptors (RyRs), were pharmacologically inhibited. Together, our findings show that, in hippocampal neurons, Ca2+ is transferred from the ER to mitochondria through IP3 receptors, and this Ca2+ crosstalk in turn enhances mitochondrial ATP production in response to neuronal activity. HighlightsO_LICa2+ adjusts mitochondrial ATP synthesis to neuronal activity C_LIO_LIIn the neuronal somata ER-mitochondria Ca2+ crosstalk occurs via IP3 receptors C_LIO_LIIP3-mediated Ca2+ release occurs across a wide range of firing intensities. C_LI

neuroscience↗

The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels

Diminished peak sodium current (INa) is a causative factor for slowed ventricular conduction and cardiac arrhythmias in patients with Duchenne muscular dystrophy (DMD), a devastating muscle disease triggered by dystrophin deficiency. Recently, we showed that chronic administration of the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) restores diminished peak INa in ventricular cardiomyocytes from the dystrophin-deficient mdx mouse model of DMD. Here, we aimed to elucidate the underlying mechanism. Whole cell patch clamp studies revealed that 24 h incubation of dystrophic (mdx) ventricular cardiomyocytes with EMPA significantly increases peak INa in a concentration-dependent manner (EC50=94 nM). The enhancing effect on peak INa also occurred in dystrophic cardiac Purkinje fibers, Nav1.5-expressing tsA201 cells, as well as in dystrophic (DMDmdx) rat cardiomyocytes, and was also exerted by two other SGLT2 inhibitors. Immunofluorescence studies suggested that chronic EMPA treatment increases Nav1.5 plasma membrane expression. Peak INa enhancement by EMPA depended on functional anterograde trafficking of Nav1.5. The local anesthetic mexiletine, a well-known pharmacological chaperone of Nav1.5, enhanced peak INa in a similar manner as EMPA. Further, mutation of human Nav1.5 at a site important for local anesthetic binding (Y1767A) completely abolished the ability of both EMPA and mexiletine to enhance peak INa. Finally, the importance of Y1767 for drug-induced modulation of peak INa was confirmed by molecular docking simulations. Our findings suggest that EMPA acts as a pharmacological chaperone of Nav1.5 channels. Its chronic administration may reduce arrhythmia vulnerability in patients with DMD and other arrhythmogenic pathologies associated with diminished peak INa.

pharmacology and toxicology↗